Madrigal Pharmaceuticals, Inc.: 5%+ holders

As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Madrigal Pharmaceuticals, Inc. The largest reported stake is Baker Bros. Advisors LP's, at 9.99%. 11 filings are on record since August 14, 2025 (Schedule 13D/A, November 6, 2026).

Paul A Friedman, M.D. also filed stake reports on 1 other company ↓

Sell to companies like Madrigal Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Event date 2026-11-06 · Holder: Baker Bros. Advisors LP · Percent: 9.99% · Shares: 2,330,144 · SCHEDULE 13D/A
• Filing 2026-07-29 · Reporting person: BlackRock, Inc. · Sole voting: 1,039,228 · Shared voting: 0 · Sole dispositive: 1,067,346 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-29
• Filed 2026-05-15 · Holder: Paulson & Co. Inc. · Percent: 6.1% · SCHEDULE 13G/A
• Filed 2026-05-15 · Holder: Janus Henderson Group Plc · Percent: 8.8% · SCHEDULE 13G/A
• Filed 2026-03-27 · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A

Madrigal Pharmaceuticals, Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Madrigal Pharmaceuticals, Inc. and the warning signs.

See Madrigal Pharmaceuticals, Inc.'s free Snapshot Watch Madrigal Pharmaceuticals, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Madrigal Pharmaceuticals, Inc. and the records around it.

Madrigal Pharmaceuticals, Inc. elsewhere on the record

• Leadership changes Aug 2026
• Who owns it

Companies that share a holder

• Paul A Friedman, M.D. also filed stake reports on 1 other company: MADRIGAL PHARMACEUTICALS, INC. (Dec 2025)
• Rebecca Taub, M.D. also filed stake reports on 1 other company: MADRIGAL PHARMACEUTICALS, INC. (Dec 2025)
• PAULSON & CO. INC. also filed stake reports on 5 other companies: INTERNATIONAL TOWER HILL MINES LTD (Apr 2026), Bausch Health Companies Inc. (Aug 2025), NOVAGOLD RESOURCES INC (Aug 2025)

Want the whole picture on Madrigal Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Madrigal Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Madrigal Pharmaceuticals, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Madrigal Pharmaceuticals, Inc. by CUSIP 558868105 and gives its principal executive office as 1001 CONSHOHOCKEN STATE ROAD, STE. 2-350, WEST CONSHOHOCKEN, PA 19428 (SCHEDULE 13D/A, 2026-11-06).

Source of funds (Item 3)

Item 3 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosure in Item 5 below is incorporated herein by reference. The Reporting Persons may in the ordinary course of business hold securities in margin accounts maintained for the Funds with prime brokers, which extend margin credit as and when required, subject to applicable margin regulations, stock exchange rules and such firms' credit policies. Positions in securities may be pledged as collateral security for the repayment of debit balances in such accounts.Baker Bros. Advisors LP, SCHEDULE 13D/A, 2026-11-06

Purpose of Transaction (Item 4)

Paul A Friedman, M.D.

No changes, except that the Reporting Person no longer serves as Chairman of the Board and Chief Executive Officer of the Issuer; the Reporting Person continues to serve as a member of the Board of Directors of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-12-12

Rebecca Taub, M.D.

No changes, except that the Reporting Person no longer serves as Chief Medical Officer of the Issuer; the Reporting Person serves as Senior Scientific and Medical Advisor of the Issuer and continues to serve as a member of the Board of Directors of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-12-12

Baker Bros. Advisors LP

Item 4 of Schedule 13D is supplemented and amended, as the case may be, as follows: This Amendment No. 5 is being filed to report the acquisition of common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") reported in Item 5(c) that resulted in a more than 1 percent change in beneficial ownership. The disclosure regarding the purchases in Item 5(c) below is incorporated herein by reference. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer's management, other members of the Board and other investors, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Depending upon their assessments of the above …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-11-06; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Madrigal Pharmaceuticals, Inc.

Who owns Madrigal Pharmaceuticals, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Madrigal Pharmaceuticals, Inc.: Baker Bros. Advisors LP (9.99%, Schedule 13D/A, filed 2026-11-06), Janus Henderson Group Plc (8.8%, Schedule 13G/A, filed 2026-05-15), Paul A Friedman, M.D. (7.8%, Schedule 13D/A, filed 2025-12-12), Rebecca Taub, M.D. (7.8%, Schedule 13D/A, filed 2025-12-12) and Paulson & Co. Inc. (6.1%, Schedule 13G/A, filed 2026-05-15).

Who are the largest shareholders of Madrigal Pharmaceuticals, Inc.?

By the share each holder's latest filing reports, the largest holders of Madrigal Pharmaceuticals, Inc. on this page are Baker Bros. Advisors LP (9.99%), Janus Henderson Group Plc (8.8%) and Paul A Friedman, M.D. (7.8%).

When did Baker Bros. Advisors LP buy into Madrigal Pharmaceuticals, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Baker Bros. Advisors LP on this page is the Schedule 13D/A, filed 2026-11-06, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Madrigal Pharmaceuticals, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Madrigal Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Madrigal Pharmaceuticals, Inc. is mentioned again
• Find former Madrigal Pharmaceuticals, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes